Meridian Small Cap Growth Fund
MSGCX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Van Kampen Investments Inc. New York NY United States of America 10036
- IPO Date
- Jul 9, 2015
- CIK
- 0000891080
- Website
- arrowmarkpartners.com
- Similar Companies
- Business
- Meridian Small Cap Growth Fund (MSGCX) is an open-end mutual fund that seeks long-term growth of capital primarily through investments in equity securities of U.S. small-capitalization growth companies, including common stocks, preferred stocks, and convertible securities; it normally invests at least 80% of its net assets in such securities with market capitalizations within the range of the Russell 2000 Growth Index. The fund offers multiple share classes, including Class A (MSGAX), Class C (MSGCX), Investor (MISGX), Legacy (MSGGX), and Institutional (MSGRX for qualified investors), with net expense ratios ranging from 1.11% to 2.26% after contractual fee waivers as of June 30, 2025; it emphasizes a research-driven process focused on high-quality companies with differentiated business models, strong competitive advantages, and downside protection. Managed by co-portfolio managers Chad Meade and Brian Schaub since inception, the fund maintains a diversified portfolio of approximately 97 holdings, with a weighted-average market cap of $2,731 million, sector allocations led by healthcare (around 29%), technology (20%), and industrials (15%), and top holdings such as Consensus Cloud Solutions Inc., Turning Point Brands Inc., and Veracyte Inc. as of September 30, 2025. The fund, part of Meridian Funds advised by ArrowMark Colorado Holdings LLC (ArrowMark Partners), was incepted on December 16, 2013, and is domiciled in the United States with operations targeted at U.S. investors through platforms available nationwide; assets under management stood at approximately $358 million as of September 30, 2025. In recent developments, ArrowMark Partners, the fund's investment adviser, entered into a technology license and services agreement in November 2025 with Mabtrx Biosciences—a subsidiary of a joint venture between ArrowMark and Viking Global Investors—for antibody discovery programs utilizing OmniAb's Omni*dAb single domain technology, under which OmniAb receives service revenues, potential equity, and royalties; this partnership underscores ArrowMark's expansion into biotech innovation and value creation initiatives. Additionally, in the third quarter of 2025, the fund trimmed its position in Zenas BioPharma following share price appreciation amid an improving biotechnology landscape and the company's agreement for up to $300 million in non-dilutive funding from Alty Pharma to advance its Obelimab clinical trial and commercialization, reflecting the managers' prudent valuation discipline. ArrowMark Partners has grown its overall assets under management to $19 billion by early 2025, maintaining a focused strategy on small-cap equities without plans for adjacent expansions.